Lv4
742 积分 2022-05-06 加入
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
2天前
已完结
Feel the breeze: Opening the therapeutic window with RIPTACs and induced proximity
10天前
已完结
VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target
13天前
已完结
Chemotherapy for renal cell carcinoma
16天前
已关闭
Renal cell carcinoma
16天前
已完结
Deoxyribonucleoside kinases: two enzyme families catalyze the same reaction
17天前
已关闭
AT1, a small molecular degrader of BRD4 based on proteolysis targeting chimera technology alleviates renal fibrosis and inflammation in diabetic nephropathy
20天前
已完结
Target and tissue selectivity of PROTAC degraders
20天前
已完结
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
20天前
已完结
Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity
20天前
已完结
皖公网安备34019202002308
